Contact
searchSearch
HMP Global
Login

Hepatocellular Carcinoma Excellence Forum

Hepatocellular Carcinoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Stephen Lam Chan, MD
Conference Coverage
Adjuvant Pembrolizumab Fails to Improve Recurrence-Free Survival in Hepatocellular Carcinoma
01/26/2026
Stephen Lam Chan, MD
Stephen Lam Chan, MD, discusses results from the phase 3 KEYNOTE-937 trial which demonstrated that adjuvant pembrolizumab did not significantly improve recurrence-free survival following curative-intent resection or local ablation for...
Stephen Lam Chan, MD, discusses results from the phase 3 KEYNOTE-937 trial which demonstrated that adjuvant pembrolizumab did not significantly improve recurrence-free survival following curative-intent resection or local ablation for...
Stephen Lam Chan, MD, discusses...
01/26/2026
Oncology
Farshid Dayyani, MD, PhD
Conference Coverage
Multimodality Immunotherapy Plus TACE Shows Promise in Liver-Limited Unresectable Hepatocellular Carcinoma
01/14/2026
Farshid Dayyani, MD, PhD
Farshid Dayyani, MD, PhD, discusses results from a phase 2 study evaluating a multimodality treatment strategy combining immunotherapy, TACE, and targeted therapy in patients with liver-limited unresectable hepatocellular carcinoma, including...
Farshid Dayyani, MD, PhD, discusses results from a phase 2 study evaluating a multimodality treatment strategy combining immunotherapy, TACE, and targeted therapy in patients with liver-limited unresectable hepatocellular carcinoma, including...
Farshid Dayyani, MD, PhD,...
01/14/2026
Oncology
Farshid Dayyani, MD, PhD
Conference Coverage
Multimodality Immunotherapy Plus TACE in Liver-Limited Unresectable Hepatocellular Carcinoma
01/14/2026
Farshid Dayyani, MD, PhD
Farshid Dayyani, MD, PhD, discusses the background and methods of a phase 2 study evaluating a multimodality treatment strategy combining immunotherapy, TACE, and targeted therapy in patients with liver-limited unresectable hepatocellular...
Farshid Dayyani, MD, PhD, discusses the background and methods of a phase 2 study evaluating a multimodality treatment strategy combining immunotherapy, TACE, and targeted therapy in patients with liver-limited unresectable hepatocellular...
Farshid Dayyani, MD, PhD,...
01/14/2026
Oncology
Nadine Abi-Jaoudeh, MD
Conference Coverage
Transarterial Tirapazamine Embolization Plus Nivolumab Shows Promise in Advanced Hepatocellular Carcinoma
01/13/2026
Nadine Abi-Jaoudeh, MD
Nadine Abi-Jaoudeh, MD, discusses results from a phase 2 study evaluating TATE combined with nivolumab in patients with advanced hepatocellular carcinoma who progressed on prior immunotherapy.
Nadine Abi-Jaoudeh, MD, discusses results from a phase 2 study evaluating TATE combined with nivolumab in patients with advanced hepatocellular carcinoma who progressed on prior immunotherapy.
Nadine Abi-Jaoudeh, MD,...
01/13/2026
Oncology
Olatunji Alese, MD, Winship Cancer Center
Videos
Dual Immune Checkpoint Blockade for Advanced Hepatocellular Carcinoma
09/17/2025
O. Alese
Olatunji Alese, MD, discusses the use of dual immune checkpoint blockade, for frontline therapy and sequencing, for patients with advanced hepatocellular carcinoma.
Olatunji Alese, MD, discusses the use of dual immune checkpoint blockade, for frontline therapy and sequencing, for patients with advanced hepatocellular carcinoma.
Olatunji Alese, MD, discusses...
09/17/2025
Oncology
Ruth He, MD
Videos
Frontline Nivolumab Plus Ipilimumab for Patients With Unresectable Hepatocellular Carcinoma
04/15/2025
Aiwu Ruth He, MD, PhD
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Ruth He, MD, PhD, discusses...
04/15/2025
Oncology
Ian Tobal, DO, Ochsner Medical Center
Videos
Real World Child-Pugh Scores of Patients With HCC Receiving Immunotherapy
03/27/2025
Ian Tobal, DO, discusses an analysis of real-world Child-Pugh score and outcomes among patients undergoing treatment for hepatocellular carcinoma.
Ian Tobal, DO, discusses an analysis of real-world Child-Pugh score and outcomes among patients undergoing treatment for hepatocellular carcinoma.
Ian Tobal, DO, discusses an...
03/27/2025
Oncology
Laura Dawson, MD, Princess Margaret Cancer Care
Videos
Addition of SBRT to Sorafenib for Patients With Locally Advanced Hepatocellular Carcinoma
03/11/2025
Laura Dawson, MD
Laura Dawson, MD, discusses the results of a phase 3 study comparing stereotactic body radiotherapy followed by sorafenib to sorafenib alone for patients with locally advanced hepatocellular carcinoma.
Laura Dawson, MD, discusses the results of a phase 3 study comparing stereotactic body radiotherapy followed by sorafenib to sorafenib alone for patients with locally advanced hepatocellular carcinoma.
Laura Dawson, MD, discusses the...
03/11/2025
Oncology
Richard Finn, MD
Videos
Tiragolumab Plus Atezolizumab and Bevacizumab for Patients With Hepatocellular Carcinoma
03/05/2025
Richard Finn, MD, discusses results from the phase 1b/2 MORPHEUS-Liver trial which demonstrated that the addition of tiragolumab to atezolizumab plus bevacizumab showed promise for patients with previously untreated, locally advanced or...
Richard Finn, MD, discusses results from the phase 1b/2 MORPHEUS-Liver trial which demonstrated that the addition of tiragolumab to atezolizumab plus bevacizumab showed promise for patients with previously untreated, locally advanced or...
Richard Finn, MD, discusses...
03/05/2025
Oncology
Boris Pasche, MD, PhD
Novel Electromagnetic Field Device for Advanced Hepatocellular Carcinoma
02/27/2025
Boris Pasche, MD, PhD
According to study results, a novel device, which emits electromagnetic fields that are amplitude-modulated at hepatocellular carcinoma frequencies, was found to have a reasonable assurance of safety and probable benefit.
According to study results, a novel device, which emits electromagnetic fields that are amplitude-modulated at hepatocellular carcinoma frequencies, was found to have a reasonable assurance of safety and probable benefit.
According to study results, a...
02/27/2025
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use